Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 115 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2015', provides an overview of the Post-Traumatic Stress Disorder (PTSD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Post-Traumatic Stress Disorder (PTSD) Overview 9
Therapeutics Development 10
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview 10
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis 11
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies 12
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes 14
Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies 19
Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes 21
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development 22
Addex Therapeutics Ltd 22
Azevan Pharmaceuticals, Inc. 23
Catalyst Pharmaceutical Partners, Inc. 24
Humanetics Corporation 25
Intra-Cellular Therapies, Inc. 26
Marinus Pharmaceuticals, Inc. 27
Nanotherapeutics, Inc. 28
Neuralstem, Inc. 29
Neurocrine Biosciences, Inc. 30
NeuroNascent, Inc. 31
Omeros Corporation 32
Otsuka Holdings Co., Ltd. 33
Polleo Pharma Limited 34
Tonix Pharmaceuticals Holding Corp. 35
Vanda Pharmaceuticals Inc. 36
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
7-Keto - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ADX-71743 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
brexpiprazole - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CPP-115 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drug for Post-Traumatic Stress Disorders - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ganaxolone - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
iloperidone - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ITI-007 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NNI-351 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NSI-189 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
NTC-942 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Rycal - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
S-107 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules for BED and PTSD - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SRX-246 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SRX-251 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
TNX-102 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Vaccine for Post-Traumatic Stress Disorder and Depression - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
verucerfont - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
vigabatrin - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ZL-006 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Post-Traumatic Stress Disorder (PTSD) - Recent Pipeline Updates 86
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects 106
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products 107
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones 108
Featured News & Press Releases 108
Jun 10, 2014: Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder 108
Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 108
Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 109
Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder 109
Oct 15, 2012: Indiana University Scientists Discover New Drug For Preventing Post-Traumatic Stress Disorder 110
Aug 30, 2012: Armgo Pharma Announces Publication Of Data Related To New Approach For Treatment Of Stress-Induced Cognitive Disorders 110
May 23, 2012: Nanotherapeutics Initiates Phase II Clinical Trial Of PRX-3140 For Treatment Of Post Traumatic Stress Disorder 111
Jun 20, 2011: Neuralstem On Schedule To Complete Phase Ia Trial Of NSI-189 In Major Depression 112
Apr 21, 2011: Marinus Announces Commencement Of Phase II Trial Of Ganaxolone In Posttraumatic Stress Disorder 112
Apr 07, 2011: Marinus Receives US Patent For Ganaxolone 113
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 115
Disclaimer 115

List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2015 10
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2015 22
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 23
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 24
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H1 2015 25
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 26
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 27
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Nanotherapeutics, Inc., H1 2015 28
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H1 2015 29
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurocrine Biosciences, Inc., H1 2015 30
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H1 2015 31
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H1 2015 32
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 33
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H1 2015 34
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 35
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Vanda Pharmaceuticals Inc., H1 2015 36
Assessment by Monotherapy Products, H1 2015 37
Number of Products by Stage and Target, H1 2015 39
Number of Products by Stage and Mechanism of Action, H1 2015 41
Number of Products by Stage and Route of Administration, H1 2015 43
Number of Products by Stage and Molecule Type, H1 2015 45
Post-Traumatic Stress Disorder (PTSD) Therapeutics - Recent Pipeline Updates, H1 2015 86
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2015 106
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2015 107